FDA Peptide Ban 2026: What Actually Changed

Key takeaways

• There is no FDA ban on owning peptides. They are not controlled substances, and nothing FDA did between 2023 and 2026 changed that. What FDA restricts is who may make and sell them.
• The "ban" most people mean is FDA's decision of September 29, 2023 to put 19 substances, mostly peptides, in Category 2 of its compounding policy, which stopped licensed pharmacies from making BPC-157, TB-500, CJC-1295, ipamorelin and the rest.
• In 2026 FDA took 12 of those peptides off Category 2 (April) and its advisory committee recommended six for the permitted list (July). Neither step made any of them compoundable, and FDA had not proposed a rule as of October 10, 2026.
• The 2026 warning letters went to sellers, not patients: 55 to telehealth companies over compounded GLP-1 marketing, and 12 to online sellers whose "research use only" labels FDA rejected.
• For GLP-1s, FDA proposed in May 2026 to keep semaglutide, tirzepatide and liraglutide off the list that lets outsourcing facilities make them in bulk. The brand drugs remain fully legal on prescription.

Is there an FDA peptide ban? No. No law or FDA action makes it a crime to own a peptide, and peptides are not controlled substances. What people call the ban is a set of separate actions that restrict who may make and sell certain peptides: a 2023 decision that stopped pharmacies compounding the popular wellness peptides, 2026 changes that loosened the label on some of them without making any legal to compound, and a year of warning letters to sellers. This page explains what each one did. The full picture of FDA's categories is in our parent guide, FDA Category 2 peptides explained; for one compound, read is BPC-157 legal?; the status of every peptide is in the legal tracker.

What each action did, and what it did not do

2023: the Category 2 placements

When a substance is nominated for FDA's list of bulk ingredients that 503A pharmacies may use, FDA sorts it into interim categories while it evaluates. Category 2 is for substances FDA says may present significant safety risks; a pharmacy that compounds with one is outside FDA's interim policy and risks enforcement. On September 29, 2023, FDA added 19 substances to it in one update, among them BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, MOTS-c, kisspeptin-10 and melanotan II (FDA categories 2023); the Category 2 guide lists all of them.

FDA's stated reasons were mostly the same for each: a possible immune response to aggregates and impurities, products that are hard to characterize, and little or no human safety data (FDA Category 2). Pharmacies stopped compounding them, and the market moved to "research" vials. That is the moment most people remember as the ban, but it was a compounding decision. It did not touch possession, and selling these peptides for human use was already illegal because none is an approved drug.

April 2026: removals that did not legalize anything

On April 15, 2026, FDA announced that 12 peptides were coming off Category 2 because their nominators had withdrawn the nominations: BPC-157, KPV, TB-500, MOTS-c, emideltide, epitalon, semax, LL-37, dihexa, injectable GHK-Cu, PEG-MGF and melanotan II (Frier Levitt 2026). Five more flagged peptides, including CJC-1295 and ipamorelin, are also on FDA's withdrawn list, which gives no date for them (FDA Category 2). By May 2026 only six substances remained in 503A Category 2, and kisspeptin-10 was the only peptide among them.

Sellers marketed this as the end of the ban. It was not. Removal ended the safety flag; it did not add any peptide to the permitted list or move any into Category 1, the only category FDA tolerates compounding from. A peptide off Category 2 still fails the three federal tests, so no licensed pharmacy may make it.

July 2026: committee votes, not a rule

On July 23 and 24, 2026, FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157 (8-6-1), KPV (8-6-1), TB-500 (8-6-1), MOTS-c (7-5-2), epitalon (7-4-1) and semax (8-5-1) for the 503A bulks list, and voted against emideltide (6-7-1) (HPM, July 24) (HPM, July 28). FDA's own reviewers had recommended against all seven.

The votes are advisory. Before any pharmacy may use these peptides, FDA must publish a proposed rule, take public comments and issue a final rule. Our search of the Federal Register on October 10, 2026 found no proposed rule. Until one is final, "recommended by FDA's committee" means exactly what it says and nothing more.

The 2026 warning letters

FDA's enforcement in 2026 targeted sellers in two groups.

Telehealth companies marketing compounded GLP-1s. FDA warned 30 companies on March 3, 2026 (FDA, March 2026) and 25 more on June 16 (Telehealth.org 2026), 55 in all, over claims that compounded semaglutide and tirzepatide were the same as, or approved like, the brand products.

Online "research peptide" sellers. Seven letters dated March 31, 2026 went to five research-peptide websites and two online marketplace sellers of GLP-1 products (Policy Canary 2026), and five more went to peptide vendors on August 24, 2026 (ArentFox Schiff 2026). Every vendor used a research-use disclaimer, and FDA rejected it because the websites showed the products were meant for people. The evidence was ordinary website content: dosing guidance, injection instructions, bundled bacteriostatic water and reconstitution calculators. Our own peptide calculator exists for the opposite case, a prescription vial with its concentration printed on a pharmacy label.

None of these letters was addressed to a patient or a buyer, and none created a new law. They applied the existing prohibition on selling unapproved drugs.

The 503B proposal: the GLP-1 piece

Semaglutide and tirzepatide are approved drugs, and the brands are fully legal on prescription. The restrictions apply to compounded copies. FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025; since then a pharmacy may compound them only for a patient with a documented clinical need the approved product cannot meet. Our guide to whether compounded tirzepatide is still legal covers that rule and the court cases.

On May 1, 2026, FDA proposed not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, the list that would let FDA-registered outsourcing facilities make them in bulk without patient-specific prescriptions (Federal Register, May 1, 2026). FDA extended the comment period to July 30, 2026 (Federal Register, June 26, 2026). As of October 10, 2026 no final decision had been published. If it is finalized, outsourcing facilities would have no clinical-need basis to make these GLP-1s; it would not change individual 503A compounding or the brand drugs. Current brand and compounded prices are in our cost guide.

What did not change: owning peptides

Peptides are not scheduled under the Controlled Substances Act. Possessing a vial of BPC-157 is not a crime, and no one is prosecuted for injecting one. The one exception that behaves like a controlled substance is human growth hormone: under 21 U.S.C. 333(e), knowingly distributing it, or possessing it with intent to distribute, for any use other than treating a disease or recognized condition where FDA has authorized that use and a physician has ordered it, is a federal felony carrying up to five years in prison, or ten if the recipient is under 18 (21 U.S.C. 333(e)). A physician's order alone does not make an unapproved use lawful.

Two practical limits remain. Importing an unapproved drug for personal use is generally not permitted, and FDA may detain it. And in tested sport, possessing a prohibited peptide is itself an anti-doping violation; is BPC-157 legal? covers the anti-doping rules, including the 2027 List.

What to watch next

Three things would change the picture: a proposed and then final rule on any of the six recommended peptides; the next committee meeting, due before the end of February 2027, on LL-37, dihexa, injectable GHK-Cu, PEG-MGF and melanotan II; and a final decision on the 503B GLP-1 proposal. We record each in the legal tracker the day it happens.

Bottom line

There was never an FDA ban on owning peptides. There was, and still is, a ban on selling unapproved peptides for human use, and since 2023 no licensed pharmacy has been allowed to compound BPC-157, TB-500, CJC-1295, ipamorelin or the other flagged peptides. The 2026 changes moved some of them closer to the permitted list without putting any of them on it, while FDA tightened enforcement against the people selling GLP-1 copies and research vials. If someone tells you "the FDA lifted the peptide ban," ask which rule they mean; as of October 2026 there is none.

Frequently asked questions

+−Did the FDA ban peptides?

Not in the sense most people mean. No FDA action makes it a crime to own a peptide, and peptides are not controlled substances. What FDA did in September 2023 was put 19 substances, mostly peptides such as BPC-157, TB-500 and CJC-1295, in Category 2 of its compounding policy, which stopped licensed pharmacies from making them. Selling unapproved peptides for human use was already illegal.

+−Are peptides illegal in the US?

No. Many peptides are FDA-approved drugs, such as insulin, semaglutide and tirzepatide, and some can be compounded by licensed pharmacies on prescription, such as sermorelin and bremelanotide. Owning a peptide is not a crime. What is illegal is selling an unapproved peptide for human use, and a licensed pharmacy compounding one that fails the federal tests.

+−Why are peptides illegal?

Most are not; the restricted ones are unapproved drugs. A peptide sold for human use without FDA approval is an unapproved new drug, whatever the label says, and a pharmacy may only compound it if it has a USP monograph, is a component of an approved drug or is on FDA's bulks list. FDA flagged the popular wellness peptides as safety risks for compounding in 2023 mainly because there were little or no human safety data and the products were hard to characterize.

+−Is the FDA banning compounded semaglutide?

Not outright. Since the semaglutide shortage ended in February 2025, a pharmacy may compound it only for a patient with a documented clinical need the approved product cannot meet, not as a copy. On May 1, 2026 FDA proposed keeping semaglutide, tirzepatide and liraglutide off the list that would let outsourcing facilities make them in bulk; comments closed July 30, 2026 and, as of October 10, 2026, FDA had not finalized it. Brand Ozempic and Wegovy are unaffected.

+−Are compounded GLP-1s going away?

They are shrinking, not disappearing by law. Mass-produced copies lost their legal basis when the shortages ended, FDA sent 55 warning letters to telehealth companies over compounded GLP-1 marketing in 2026, and its 503B proposal would remove the outsourcing-facility route. Individual compounding for a documented clinical need remains legal under 503A.

+−Did FDA lift the ban on BPC-157 in 2026?

No. FDA took BPC-157 off its Category 2 list on April 15, 2026 because its nomination was withdrawn, and its advisory committee recommended it 8 to 6 with one abstention in July 2026. Neither step lets a pharmacy compound it. FDA must publish and finalize a rule first, and as of October 10, 2026 it has not proposed one.

+−What is on the FDA peptide ban list?

There is no single ban list. The closest thing is Category 2 of FDA's interim compounding policy, which for 503A pharmacies now holds six substances, of which kisspeptin-10 is the only peptide. Seventeen peptides that were flagged in 2023, including BPC-157, TB-500, CJC-1295 and ipamorelin, are now on FDA's withdrawn list, and none of them can be compounded.

+−Can I get in trouble for having peptides?

Not under federal drug law for simple possession: peptides are not controlled substances. Human growth hormone is the exception that behaves like one, because distributing it, or possessing it with intent to distribute, for an unapproved use is a federal crime. Importing an unapproved drug for personal use is generally not permitted and may be detained. In tested sport, possessing a prohibited peptide is itself an anti-doping violation.

Sources

1. RegulatoryFDA. Bulk drug substances nominated for use in compounding under section 503A: notice of updates to categories (19 substances added to Category 2), updated September 29, 2023. Copy hosted by the Alliance for Pharmacy Compounding; read October 10, 2026. (2023)
2. RegulatoryFDA. Certain bulk drug substances for use in compounding that may present significant safety risks: Category 2, and substances nominated but withdrawn (content current as of April 22, 2026). Read October 10, 2026. (2026)
3. NewsFrier Levitt. FDA to remove 12 popular peptides from the Category 2 'do not compound' list. April 16, 2026. (2026)
4. NewsPalmer KL, Snow CD, Bass M. PCAC approves four bulk drug substances for the 503A list (BPC-157, KPV, TB-500, MOTS-c). FDA Law Blog, Hyman Phelps & McNamara, July 24, 2026. (2026)
5. NewsSnow CD, Palmer KL, Bass M. PCAC adds two more bulk drug substances for the 503A list (epitalon, semax; emideltide rejected). FDA Law Blog, July 28, 2026. (2026)
6. RegulatoryFDA. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. Press announcement, March 2026. (2026)
7. NewsTelehealth.org. FDA sends new round of warning letters (25 companies) over compounded GLP-1 marketing claims. June 2026. (2026)
8. NewsPolicy Canary. The research use only loophole just closed: FDA hits seven peptide websites in a single day (warning letters dated March 31, 2026, posted April 7, 2026). April 21, 2026. (2026)
9. NewsArentFox Schiff. RUO-ined: five peptide vendors learn that research use only is not a legal strategy (FDA warning letters of August 24, 2026). September 18, 2026. (2026)
10. RegulatoryFederal Register. List of bulk drug substances for which there is a clinical need under section 503B: FDA proposes not to include semaglutide, tirzepatide and liraglutide. May 1, 2026. (2026)
11. RegulatoryFederal Register. List of bulk drug substances for which there is a clinical need under section 503B; extension of comment period to July 30, 2026. June 26, 2026. (2026)
12. Regulatory21 U.S.C. 333(e): prohibited distribution of human growth hormone.